🧴 Cosmetic Peptide Regulation¶
Since China's cosmetics industry entered the efficacy evaluation era, the filing compliance and efficacy claims of cosmetic peptide ingredients must satisfy the strict requirements of the "Cosmetic Supervision and Administration Regulation" (effective 2021) and its supporting rules. This chapter systematically outlines China's cosmetic peptide registration, safety assessment, and efficacy claim regulatory framework, with international comparisons.
1. NMPA Cosmetic Ingredient Filing System¶
| Ingredient Type | Management Method | Regulatory Basis | Filing Process | Cycle |
|---|---|---|---|---|
| Listed in Inventory of Existing Ingredients | Filing | "Inventory of Existing Cosmetic Ingredients" (2021 Edition) | Submit filing info → Submit safety assessment | 3–6 months |
| New Ingredient (General) | Filing | "Cosmetic New Ingredient Registration and Filing Data Management Rules" | Toxicology assessment → Filing → 3-year monitoring period | 6–12 months |
| New Ingredient (High-Risk) | Registration | "Cosmetic New Ingredient Registration and Filing Data Management Rules" | Registration approval → 5-year monitoring period | 12–24 months |
Importance of the Existing Inventory
Major cosmetic peptides such as Copper Tripeptide, Acetyl Hexapeptide-8, and Palmitoyl Pentapeptide-4 are included in the "Inventory of Existing Cosmetic Ingredients" (2021 Edition). Peptide ingredients within this inventory can be managed as general cosmetic ingredients through the filing system, without requiring new ingredient registration. However, if structural modifications fall outside the inventory scope, new ingredient management procedures apply.
2. Peptide Ingredients in the Inventory of Existing Cosmetic Ingredients (IESL)¶
The following table lists the major peptide ingredients included in the Inventory of Existing Cosmetic Ingredients (2021 Edition):
| Chinese Name | INCI Name | Usage Limit | Primary Function | Filing Status |
|---|---|---|---|---|
| 乙酰基六肽-8 | Acetyl Hexapeptide-8 | ≤10% | Anti-wrinkle, Botox-like effect | Existing |
| 棕榈酰五肽-4 | Palmitoyl Pentapeptide-4 | ≤5% | Anti-wrinkle, collagen synthesis promotion | Existing |
| 棕榈酰三肽-1 | Palmitoyl Tripeptide-1 | ≤5% | Anti-wrinkle, repair | Existing |
| 棕榈酰四肽-7 | Palmitoyl Tetrapeptide-7 | ≤3% | Anti-inflammatory, anti-aging | Existing |
| 铜肽（三肽-1铜） | Copper Tripeptide-1 | ≤1% | Repair, antioxidant | Existing |
| 乙酰基四肽-2 | Acetyl Tetrapeptide-2 | ≤5% | Anti-wrinkle, firming | Existing |
| 乙酰基二肽-1鲸蜡酯 | Acetyl Dipeptide-1 Cetyl Ester | ≤3% | Anti-wrinkle | Existing |
| 乙酰基七肽-4 | Acetyl Heptapeptide-4 | ≤3% | Anti-wrinkle | Existing |
| 乙酰基八肽-3 | Acetyl Octapeptide-3 | ≤5% | Expression line reduction | Existing |
| 六肽-9 | Hexapeptide-9 | ≤5% | Firming, lifting | Existing |
| 五肽-3 | Pentapeptide-3 | ≤5% | Anti-wrinkle | Existing |
| 三肽-10瓜氨酸 | Tripeptide-10 Citrulline | ≤3% | Repair, anti-inflammatory | Existing |
| 二肽-2 | Dipeptide-2 | ≤3% | Firming | Existing |
| 棕榈酰六肽-12 | Palmitoyl Hexapeptide-12 | ≤5% | Anti-aging, elastin synthesis | Existing |
| 乙酰基六肽-1 | Acetyl Hexapeptide-1 | ≤10% | Anti-wrinkle | Existing |
| 肌肽 | Carnosine | ≤5% | Antioxidant, anti-glycation | Existing |
| 乙酰基十肽-3 | Acetyl Decapeptide-3 | ≤5% | Anti-wrinkle | Existing |
Inventory Usage Notes
Although peptide ingredients in the existing inventory can be used directly via filing, note that: - Usage concentration should not exceed the historical concentration listed in the inventory or the company's self-established safe usage level - If usage exceeds historical concentration, additional safety assessment data must be submitted - The inventory is periodically updated (last update: 2021 Edition; next edition expected end of 2025); watch for added or adjusted entries
3. Cosmetic Peptide Safety Assessment Requirements¶
Per the "Technical Guidelines for Cosmetic Safety Assessment" (2024 Edition), peptide-containing cosmetic products must submit the following:
| Assessment Item | Requirement | Applicable Peptides | Suggested Exemption Conditions |
|---|---|---|---|
| Ingredient Safety Information | MSDS, COA, heavy metal/microbial testing | All peptide ingredients | Mandatory |
| Skin Irritation/Sensitization | Human/animal skin irritation test | All peptide-containing products | Exempt if sufficient historical safe use data exists |
| Phototoxicity | 3T3 NRU phototoxicity test | Peptides with photosensitive groups | Exempt if no UV absorption |
| Local Toxicity | Skin irritation/allergy/phototoxicity tests | All peptide-containing products | — |
| Systemic Toxicity | Repeat-dose toxicity, reproductive toxicity, mutagenicity | Highly permeable small-molecule peptides (MW <500 Da) | Exempt if MW >500 Da or no transdermal evidence |
| Mutagenicity | Ames test + chromosome aberration test | Synthetic peptide ingredients | Exempt if no structural alerts |
| Stability | Accelerated study (40°C/6 months) | All peptide products | — |
| Preservation Efficacy | PET (Preservation Efficacy Test) | Peptide formulations need antimicrobial system compatibility | — |
| Impurity Control | Synthetic by-product (EPC/DPA) residue limits | Chemically synthesized peptides | Simplified if purity >99% |
| Transdermal Absorption Study | Franz diffusion cell / human stratum corneum model | Active ingredient safety evaluation | Generally not required if MW >1,000 Da |
Safety Assessment Report Writing Essentials¶
| Safety Assessment Module | Content Requirements | Evidence Type | Reference Standard |
|---|---|---|---|
| Ingredient Physicochemical Properties | Molecular weight, solubility, LogP, pKa | Literature/measured | OECD guidelines |
| Toxicological Endpoints | Acute toxicity, irritation, sensitization, phototoxicity | Toxicology test reports | CNAS-accredited lab |
| Systemic Toxicity Assessment | MOE (Margin of Exposure) calculation | Systemic exposure dose estimation | SCCS guidelines |
| Impurity Toxicology | EPC/DPA/residual solvents/heavy metals | Impurity profile + toxicological threshold | ICH Q3C/Q3D |
| Stability Assessment | Chemical stability, microbiological stability | Accelerated/long-term stability data | Cosmetic stability guidelines |
| Risk Assessment Conclusion | Safe use conditions, concentration, warnings | Comprehensive assessment | Safety assessment guidelines |
4. Efficacy Claims and Evaluation Methods¶
| Efficacy Category | Permitted Claims | Evaluation Method | Testing Instruments / Method | Subjects | Evidence Level Required | Est. Cost (¥10K) |
|---|---|---|---|---|---|---|
| Anti-Wrinkle | Improves wrinkles, reduces fine lines | Human efficacy evaluation | VISIA-CR / skin fast imaging | ≥30 | High | 15–25 |
| Firming | Improves skin elasticity, firmness | Human efficacy evaluation | Cutometer / elasticity test | ≥30 | High | 10–20 |
| Anti-Aging | Delays skin aging | Human + in vitro dual validation | VISIA + collagen synthesis assay | ≥30 | High | 25–40 |
| Moisturizing | Improves skin hydration | Human efficacy evaluation | Corneometer | ≥30 | Medium | 5–10 |
| Repair | Repairs skin barrier | Human efficacy evaluation | TEWL test (Tewameter) | ≥30 | Medium-High | 10–15 |
| Anti-Inflammatory/Soothing | Soothes sensitivity, reduces redness | Human efficacy evaluation | Erythema index (Mexameter) | ≥30 | Medium | 8–15 |
| Acne Treatment | Reduces blackheads/acne | Human efficacy evaluation | Sebum measurement / VISIA | ≥30 | Medium-High | 10–18 |
| Antioxidant | Resists oxidative damage | In vitro + literature | DPPH/ORAC method / cell assay | N/A | Medium-Low | 3–8 |
Efficacy Evaluation Strategy Selection¶
| Strategy | Applicable Scenario | Advantages | Disadvantages |
|---|---|---|---|
| Human Efficacy Evaluation (Gold Standard) | Anti-aging/anti-wrinkle/firming core claims | Highest evidence level, strong compliance | High cost (¥100K–400K), long cycle (3–6 months) |
| In Vitro Efficacy Evaluation | Supporting claims / mechanism substantiation | Low cost, short cycle | Cannot serve as standalone efficacy evidence |
| Consumer Test (>50-person survey) | Supporting claims / product storytelling | Moderate cost, quantifiable | Cannot replace human instrument testing |
| Literature Citation | Known efficacy, well-established ingredients | Zero cost | Must verify literature relevance and timeliness |
Efficacy Evaluation Strategy Recommendations
- Gold Standard: Anti-aging/anti-wrinkle products with peptides must complete human efficacy evaluation (at least 30 subjects) using quantitative instruments such as VISIA or Cutometer
- Alternative Path: Consumer tests (>50-person questionnaire) can support auxiliary claims but cannot replace human instrument testing
- In Vitro Data Support: Collagen synthesis quantity, MMP-1 inhibition rate, and other in vitro results can serve as mechanism substantiation
- Cost Optimization: Multi-peptide combination products can undergo single-formulation human evaluation, with multiple claims sharing evaluation data
5. Restricted / Monitored Peptide Ingredients¶
| Ingredient | Current Status | Reason for Restriction | Compliance Requirement |
|---|---|---|---|
| Snake Venom Mimetic Peptide (SYN-AKE) | Under debate | Some components not in the inventory | Must register as new ingredient |
| High-Concentration Copper Peptide (>1%) | Enhanced monitoring | Excess copper ions may cause irritation | Submit high-concentration safety assessment |
| Unlisted Synthetic Peptides | Non-compliant | Not in the existing inventory | Requires new ingredient registration or filing |
| Botulinum Toxin Mimetic Peptides | Enhanced oversight | May affect neurotransmitter release | Must register as new ingredient (high-risk category) |
6. Peptide-Containing Cosmetic Registration Process¶
Ingredient Compliance Confirmation
↓
Formulation Development (Peptide Compatibility Stability Testing)
↓
Efficacy Evaluation (Human / In Vitro / Consumer Testing)
↓
Safety Assessment Report (Toxicology + Formulation Safety)
↓
Filing Submission (NMPA Filing Platform)
↓
Post-Filing Supervision and Management (3-year monitoring period)
| Phase | Estimated Duration | Key Milestones |
|---|---|---|
| Ingredient Assessment | 1–2 months | Confirm ingredient is in existing inventory |
| Formulation Development | 2–4 months | Stability/compatibility/preservation challenge testing |
| Efficacy Evaluation | 3–6 months | Human efficacy report is most time-consuming |
| Filing Approval | 2–4 months | NMPA formal review + filing certificate |
7. International Cosmetic Peptide Regulation Comparison¶
| Comparison Dimension | China (NMPA) | European Union (EU) | United States (FDA) |
|---|---|---|---|
| Regulatory Framework | Cosmetic Supervision and Administration Regulation (2021) | EU Cosmetics Regulation 1223/2009 | FD&C Act + MoCRA (2023 update) |
| Ingredient Management | Existing inventory / new ingredient registration and filing | Prohibited/restricted lists + active filing (CPNP) | Voluntary registration (VCRP) + prohibited list |
| New Ingredient Evaluation | Safety + efficacy + monitoring period | Safety assessment report (CPSR) | Safety assessment (company's own responsibility) |
| Efficacy Claim Management | Strict (requires human efficacy evidence) | Moderate (requires sufficient evidence, CE marking) | Relaxed (no pre-approval, FTC oversight) |
| Special Peptide Requirements | Peptides in existing inventory can be used directly | Must ensure record in CosIng database | Generally Recognized as Safe (GRAS) or NMI |
| Safety Assessment Cycle | 6–12 months (filing) + 3-year monitoring | 4–8 months (CPNP filing) | Company's own responsibility |
| Animal Testing | Gradually restricted (alternative methods encouraged) | Fully banned (effective 2013) | Partially accepted (MoCRA promoting alternatives) |
| Label Ingredient Identification | INCI name + Chinese standard name | INCI name | INCI name |
International Benchmarking Insights
China's cosmetic regulatory system has approached or even exceeded EU standards in certain dimensions (e.g., strictness of efficacy claim management), though new ingredient management remains differentiated. For peptide-containing cosmetic companies targeting all three markets (China, EU, US), recommended strategies include: - Use INCI names for unified ingredient identification to reduce multi-market registration costs - Human efficacy evaluation data satisfying China's requirements can also serve as supplementary data for EU/US filings - Closely monitor new US ingredient filing requirements under MoCRA during the 2024–2025 transition period
Regulatory Basis: "Cosmetic Supervision and Administration Regulation" (2021), "Cosmetic Registration and Filing Management Measures," "Technical Guidelines for Cosmetic Safety Assessment" (2024 Edition), "Cosmetic Efficacy Claims Evaluation Standards." The above information is general reference only; specific product registration pathways should be determined based on ingredient characteristics and formulation complexity. For cosmetic peptide compliance consulting, safety assessment report writing, or efficacy evaluation plan design — contact the cosmetic peptide compliance services for one-stop compliance solutions covering cosmetic peptide regulatory filing services across China, the EU, and the US.